1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Butrans Pediatric Labeling Draws Mixed Views At US FDA Panel

 
• By Sue Sutter

Opponents say including data from a small pediatric trial of Purdue's buprenorphine patch could give the impression the study was more robust than it actually was, while supporters say labeling should reflect any available data that can inform pediatric prescribing.

Small kid taking a view of a plastic house.

A US FDA advisory committee's divided opinion on adding pediatric study data to Purdue Pharma LP's Butrans (buprenorphine extended release transdermal) labeling reflects a struggle between the desire to give healthcare providers all available information on dosing and safety in children and the concern that pediatric labeling would expand off-label use in this population.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers